Working… Menu

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02785250
Recruitment Status : Unknown
Verified January 2019 by ImmunoVaccine Technologies, Inc. (IMV Inc.).
Recruitment status was:  Active, not recruiting
First Posted : May 27, 2016
Last Update Posted : January 9, 2020
Incyte Corporation
Information provided by (Responsible Party):
ImmunoVaccine Technologies, Inc. (IMV Inc.)

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : December 2020